Literature DB >> 11355786

Clinical significance of reverse redistribution on resting thallium-201 imaging in patients with vasospastic angina.

A Nakano1, J D Lee, H Shimizu, A Tsubokawa, H Uzui, T Tsuchida, N Takahashi, Y Yonekura, T Ueda.   

Abstract

To evaluate the clinical significance of reverse redistribution (RR) of resting 201Tl single photon emission computed tomography (SPECT) in patients with vasospastic angina (VSA), we performed left ventriculography, coronary angiography and resting 201Tl-SPECT in 22 patients with VSA. Left ventriculography showed abnormal wall motion in 17 of 22 patients (77%) and 37 of 154 segments. Thirty-one of these 37 segments (84%) were within the area perfused by coronary arteries showing acetylcholine-induced vasospasm. On 201Tl images, abnormal findings were observed in 11 of 22 patients (50%), and among them, 7 patients (32%) had RR. Seven of 37 segments (19%) having abnormal regional wall motion had RR of 201TI, and in 6 of these 7 segments (86%), accumulation of 123I-BMIPP was found to be reduced. We conclude that repetitive brief myocardial ischemia may cause myocardial injuries in patients with VSA, and that the presence of RR of 201Tl indicates the presence of myocardial injury in these patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11355786     DOI: 10.1007/bf03012135

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  2 in total

1.  Investigation of the mechanism of reverse redistribution in thallium-201 myocardial perfusion scintigraphy in patients with suspicion for coronary artery spasm.

Authors:  Dingcheng Xiang; Zhenhong Xie; Jinhe Zhang; Jilin Yin
Journal:  J Nucl Cardiol       Date:  2011-02-17       Impact factor: 5.952

Review 2.  Non-invasive diagnosis of vasospastic angina.

Authors:  Vincent Ngo; Anahita Tavoosi; Alexandre Natalis; Francois Harel; E Marc Jolicoeur; Robert S B Beanlands; Matthieu Pelletier-Galarneau
Journal:  J Nucl Cardiol       Date:  2022-03-23       Impact factor: 5.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.